newsfilter
← Latest News
GlobeNewswire·

Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine's Potential Across Multiple Neuropsychiatric Indications

RVPH
  • Reviva Pharmaceuticals Holdings Inc. announced that CEO Laxminarayan Bhat will participate in a fireside chat with A.G.P. Equity Research Analyst James Molloy on Monday, April 27, 2026, at 11:00 AM ET.
  • The event will highlight recent clinical developments regarding the drug candidate brilaroxazine along with upcoming regulatory & IP milestones.
  • Brilaroxazine is an in-house discovered new chemical entity targeting serotonin & dopamine receptors for conditions including schizophrenia, psoriasis, pulmonary hypertension (PAH), & idiopathic pulmonary fibrosis (IPF).
  • The Phase 3 RECOVER trial for schizophrenia met all primary & secondary endpoints, showing statistically significant reductions in major symptom domains & proinflammatory cytokines at week 4 with a 50 mg dose.
  • Side effects for brilaroxazine were generally well-tolerated, with a safety profile comparable to placebo & lower discontinuation rates than placebo.
  • Clinical drug-drug interaction studies indicate no clinically significant interaction when brilaroxazine is combined with CYP3A4 inhibitors.
  • Reviva believes regulatory compliant toxicology & safety pharmacology studies for brilaroxazine are complete.
  • The company intends to develop brilaroxazine for additional neuropsychiatric indications including bipolar disorder, major depressive disorder (MDD), & attention-deficit-hyperactivity disorder (ADHD).
  • Nonclinical data shows brilaroxazine mitigates fibrosis & inflammation in animal models for psoriasis, PAH, & IPF.
  • The FDA has granted Orphan Drug Designation to brilaroxazine for the treatment of PAH & IPF.
  • Reviva's pipeline includes two in-house discovered new chemical entities: brilaroxazine (RP5063) & RP1208.
  • Reviva has been granted composition of matter patents for both candidates in the United States, Europe, & other countries.